351 related articles for article (PubMed ID: 6127351)
21. Treatment of hyperkinetic movement disorders.
Bressman SB; Greene PE
Neurol Clin; 1990 Feb; 8(1):51-75. PubMed ID: 2181268
[TBL] [Abstract][Full Text] [Related]
22. Cocaine-related movement disorders.
Cardoso FE; Jankovic J
Mov Disord; 1993 Apr; 8(2):175-8. PubMed ID: 8474485
[TBL] [Abstract][Full Text] [Related]
23. Orofacial movement disorders.
Balasubramaniam R; Ram S
Oral Maxillofac Surg Clin North Am; 2008 May; 20(2):273-85, vii. PubMed ID: 18343330
[TBL] [Abstract][Full Text] [Related]
24. Inherited movement disorders.
Harding AE
Baillieres Clin Neurol; 1994 Aug; 3(2):259-79. PubMed ID: 7952847
[TBL] [Abstract][Full Text] [Related]
25. [Nicotine in neuropsychiatric movement disorders].
Erdmann R
Fortschr Neurol Psychiatr; 1996 Sep; 64(9):362-6. PubMed ID: 8991874
[TBL] [Abstract][Full Text] [Related]
26. GABA and movement disorders.
Marsden CD; Sheehy MP
Adv Biochem Psychopharmacol; 1981; 30():225-34. PubMed ID: 6460427
[No Abstract] [Full Text] [Related]
27. Blepharospasm-oromandibular dystonia syndrome (Meige's syndrome): clinical aspects.
Tolosa E; Martà MJ
Adv Neurol; 1988; 49():73-84. PubMed ID: 3278555
[TBL] [Abstract][Full Text] [Related]
28. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
Tolosa ES
Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
[No Abstract] [Full Text] [Related]
29. Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome.
Kompoliti K; Goetz CG
Mov Disord; 1998 May; 13(3):477-80. PubMed ID: 9613740
[TBL] [Abstract][Full Text] [Related]
30. Advances in understanding L-DOPA-induced dyskinesia.
Cenci MA; Lindgren HS
Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
[TBL] [Abstract][Full Text] [Related]
31. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
32. Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia.
Wilbur R; Kulik FA; Kulik AV
Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):849-64. PubMed ID: 2907387
[TBL] [Abstract][Full Text] [Related]
33. Sensory phenomena in Tourette's syndrome.
Scahill LD; Leckman JF; Marek KL
Adv Neurol; 1995; 65():273-80. PubMed ID: 7872145
[TBL] [Abstract][Full Text] [Related]
34. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.
Jankovic J; Orman J
Neurology; 1988 Mar; 38(3):391-4. PubMed ID: 3279337
[TBL] [Abstract][Full Text] [Related]
35. The pharmacology of extrapyramidal movement disorders.
Klawans HL
Monogr Neural Sci; 1973; 2():1-136. PubMed ID: 4271860
[No Abstract] [Full Text] [Related]
36. [Neurologic indications for bromocriptine (in addition to Parkinson's disease)].
Destee A
LARC Med; 1984 Feb; 4(2):107-11. PubMed ID: 6232436
[No Abstract] [Full Text] [Related]
37. Orofacial dyskinesias and dystonia in rats infected with Borna disease virus; a model for tardive dyskinetic syndromes.
Solbrig M; Koob G; Lipkin W
Mol Psychiatry; 1999 Jul; 4(4):310-2. PubMed ID: 10483043
[TBL] [Abstract][Full Text] [Related]
38. Clozapine therapy for Parkinson's disease and other movement disorders.
Pfeiffer C; Wagner ML
Am J Hosp Pharm; 1994 Dec; 51(24):3047-53. PubMed ID: 7856623
[TBL] [Abstract][Full Text] [Related]
39. [The electrophysiological approach to tardive dyskinesias].
Rondot P
Encephale; 1988 Sep; 14 Spec No():183-9. PubMed ID: 2905645
[TBL] [Abstract][Full Text] [Related]
40. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
